The 2nd U.S. Circuit Court of Appeals indicated that an alleged monopolist’s appointment of an exclusive distributorship for its lumber products did not violate the antitrust laws. A district court ruled that plaintiffs presented sufficient evidence at trial to support a finding that generic anti-anxiety drugs constituted a separate relevant market to the exclusion of brand name versions of the same drugs.
Other recent antitrust developments of interest included approval by the Federal Trade Commission of the combination of two of three domestic munitions producers subject to the acquiring firm’s divestiture of its 50 percent interest in the third producer.
